Biopharma AI
By
Could the Algen Biotechnologies – AstraZeneca $555 Million AI-Driven Drug-Discovery Pact Redefine How Immunology Therapies Are Developed?
Key Highlights / Executive Take-aways: Strategic Significance of the PartnershipThe alliance between Algen Biotechnologies and AstraZeneca marks a…
Can Takeda and Nabla Bio’s $1 Billion AI Alliance Redefine the Future of Protein Therapeutics?
Key Highlights: AI Takes Center Stage in Takeda’s R&D RebootAfter narrowing its research focus to small molecules, biologics,…
Can GHX’s AI-Driven Supply Chain Solutions Transform How Hospitals Tackle Disruptions?
Key Highlights AI reshaping healthcare supply chains: Unlike retail or tech, healthcare requires flawless delivery—any delay can directly…
Is Stanford’s MedAgentBench Setting the New Gold Standard for AI in Clinical Care?
Key Highlights AI benchmarking moves beyond knowledge tests: Unlike earlier evaluations that focused on exams like the USMLE,…
Adaptive Biotechnologies and Pfizer Announce Strategic Research Collaboration Valued Up to $890 Million to Advance Breakthrough Therapies for Rheumatoid Arthritis and Immune-Mediated Diseases
A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis. A data licensing agreement to…
Is Merck and Nvidia’s KERMT Model the Breakthrough That Finally Makes AI-Native Drug Discovery Faster, Greener, and More Predictive?
Key Highlights / Executive Takeaways: • Merck and Nvidia introduce KERMT, a next-generation small-molecule AI model trained on…
